Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Broker tips: Iofina, Beazley

(Sharecast News) - Analysts at Canaccord Genuity initiated coverage on specialty chemicals group Iofina at 'buy' on Monday as it pointed to a "strong return profile ahead". Canaccord said Iofina's vertical integration gave it a "significant cost advantage" over competing iodine suppliers, which were primarily in Chile. It also said Iodine has "attractive long-term growth characteristics" and was currently experiencing "significant supply tightness".

"We expect this to continue well into 2023, and potentially beyond, allowing Iofina to benefit from premium returns," said Canaccord.

The Canadian bank believes Iofina's "successful transition" to being not only free cash positive, but also its "exceptionally robust balance sheet", was underrated in the market.

Canaccord Genuity started the stock off with a 35.0p target, based primarily on multiples, meaning the stock would trade at 13x/15x 2023E/24E price-to-earnings ratio at its target price.

"We believe earnings for FY22E are likely to be in the range of EBITDA $8.5-9.5m; we expect FY23E to be somewhat stronger due to the mix of lagged contract pricing, improved cost recovery, and some volume increase from the 1H23 start-up of IO#9. The group is not wasting current profits and is investing in chemical as well as further IOsorb plants. It has been free cash generative throughout the past five years and we expect will be able to continue this record over the next three years," said the analysts.

Analysts at Berenberg slightly raised their target price on insurance firm Beazley from 720.0p to 750.0p on Monday, stating profitable growth looked set to accelerate.

Berenberg updated its forecasts on the stock to reflect Beazley's £350.0m capital raise on 16 November and added that the firm's rationale for growing its property franchise made "perfect sense" and that the timing was "fortuitous" given "very strong" momentum in its cyber business.

"In our view, this capital allocation decision is a bold statement about Beazley's confidence in the outlook for its cyber business," said Berenberg. "We think 2023E will involve a step-up in Beazley's scale: we estimate the company will be 2.7x the size it was in 2017 in terms of net premiums."

The German bank now forecasts net premium growth to accelerate "significantly" to 28.5% in 2023, up from 15% before.

"We estimate a circa 24% compound annual growth in net asset value per share between H122 and FY24E which, in our view, will be very difficult for other companies in the sector to match," said Berenberg, which also reiterated its 'buy' rating on the stock. "This makes Beazley one of the most attractive profitable growth stories in insurance."

Share this article

Related Sharecast Articles

Broker tips: Volution, Videndum
(Sharecast News) - Jefferies reiterated its 'buy' rating and 510.0p target price on Volution on Wednesday as it said the company's ability to drive margins higher, through both revenue mix and efficiency, is more than offsetting the challenging market backdrop to deliver ongoing earning upgrades.
Broker tips: Marlowe, Fevertree
(Sharecast News) - Analysts at Berenberg slightly lowered their target price on software and services firm Marlowe from 720.0p to 710.0p on Tuesday but said the group's divestment of certain Governance, Risk and Compliance software and service assets had left it with a "much cleaner and simpler-to-understand equity story".
Broker tips: JD Sports, NatWest
(Sharecast News) - Barclays downgraded JD Sports on Monday to 'equalweight' from 'overweight' and cut its price target for the stock to 140.0p from 165.0p after the retailer announced the acquisition of US rival Hibbett last week for $1.1bn.
Broker tips: NatWest, Pensionbee, Greggs
(Sharecast News) - Shore Capital reiterated its 'buy' rating on bank NatWest after a forecast-beating first quarter but said it sees the least amount of upside potential in the stock compared with the wider banking sector.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.